SonoThera Appoints Adam J. Shaywitz, M.D., Ph.D., as Chief Medical Officer to Advance Genetic Medicine Pipeline
SonoThera, a biotechnology company developing next-generation genetic medicines designed to address the underlying causes of disease, has appointed Adam J. Shaywitz, M.D., Ph.D., as Chief Medical Officer. The appointment adds an experienced clinical development leader to SonoThera’s executive team as the company prepares to advance its genetic medicine pipeline toward clinical development.
Dr. Shaywitz brings approximately two decades of experience in the biopharmaceutical industry, with expertise spanning early- and late-stage drug development, genetic medicines, rare diseases and emerging therapeutic platforms. Throughout his career, he has worked across multiple stages of drug development, helping translate innovative scientific approaches from preclinical research into clinical programs and advance them through important development and regulatory milestones.
At SonoThera, Shaywitz will provide medical and clinical leadership as the company works to move its technology and pipeline toward the clinic. His responsibilities are expected to include helping establish clinical development strategies, shaping translational plans and supporting the advancement of potential genetic medicine candidates into human studies.
The appointment comes as SonoThera seeks to address some of the longstanding challenges associated with delivering genetic medicines to patients. The company is developing its technology with the goal of expanding the reach of genetic therapies and potentially enabling new treatment approaches for diseases where existing therapeutic options remain limited.
Experienced Leader in Genetic Medicine Development
SonoThera Chief Executive Officer and Co-Founder Kenneth Greenberg, Ph.D., said Shaywitz brings a combination of clinical development expertise and genetic medicine experience that will be particularly valuable as the company prepares for clinical-stage development.
“Adam brings an exceptional combination of clinical development expertise, deep experience in genetic medicines, and a track record of advancing innovative science from preclinical research into clinical development,” Greenberg said.
He added that Shaywitz’s translational and clinical experience will be important in helping SonoThera shape its development strategy and realize the potential of its technology for patients.
Shaywitz’s background includes leadership positions at companies developing gene therapies and other advanced medicines for rare diseases. His experience encompasses clinical strategy, medical development, regulatory interactions and organizational leadership, providing him with an understanding of the challenges involved in moving novel genetic medicine platforms through development.
His most recent position was Chief Medical Officer of BridgeBio Gene Therapy, where he led clinical and medical strategy across a portfolio of gene therapy programs. During his tenure, he also helped establish a multidisciplinary clinical development organization designed to support the advancement of multiple programs.
Among the programs he supported were adeno-associated virus, or AAV, gene therapies targeting monogenic diseases. These included programs for congenital adrenal hyperplasia and Canavan disease, two rare conditions associated with genetic abnormalities.
His work at BridgeBio Gene Therapy included helping advance AAV-based programs through significant clinical and regulatory milestones. He also contributed to securing Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration for BBP-812, an investigational AAV9 gene therapy being developed for Canavan disease.
The experience provides Shaywitz with direct exposure to the clinical and regulatory considerations involved in developing genetic medicines for patients with serious rare diseases.
Focus on Overcoming Genetic Medicine Delivery Challenges
A central element of SonoThera’s technology strategy is addressing delivery challenges that have historically limited the application of genetic medicines.
While genetic medicine technologies have demonstrated the potential to address disease at its biological source, the ability to deliver therapeutic genetic material to the appropriate cells and tissues remains an important challenge. Delivery limitations can affect which diseases can be targeted, how therapies are administered and whether therapeutic levels of genetic material can reach the intended site of action.
SonoThera is developing next-generation genetic medicine technologies intended to address these challenges and potentially broaden the therapeutic applications of genetic medicines.
Shaywitz said the company’s approach could provide an opportunity to overcome fundamental limitations that have constrained the field.
“SonoThera’s approach has the potential to overcome fundamental delivery challenges that have limited the reach of genetic medicines,” Shaywitz said.
He added that he was excited to join Greenberg and the SonoThera team at an important stage in the company’s development and to help translate its technology into new potential treatment options for patients.
His appointment therefore comes at a point when the company is transitioning from technology development toward clinical application, making clinical strategy and translational expertise particularly important.
Leadership Experience at BridgeBio Gene Therapy
Shaywitz’s experience at BridgeBio Gene Therapy represents a significant portion of his background in genetic medicine development.
As Chief Medical Officer, he was responsible for clinical and medical strategy across a portfolio of gene therapy programs. His responsibilities extended beyond individual development programs to include building a multidisciplinary clinical development organization capable of supporting programs through different stages.
The AAV gene therapy programs under his leadership focused on monogenic conditions, which are diseases caused by changes in individual genes. These diseases can be particularly well suited to genetic medicine approaches because correcting or replacing a defective genetic function may directly address an underlying cause of disease.
At BridgeBio, Shaywitz helped advance programs targeting congenital adrenal hyperplasia and Canavan disease through key clinical and regulatory milestones.
His work on BBP-812 is another example of his regulatory development experience. The investigational AAV9 gene therapy for Canavan disease received RMAT designation from the FDA. The designation is intended to facilitate development of regenerative medicine therapies addressing serious or life-threatening diseases when preliminary clinical evidence indicates the potential to address an unmet medical need.
Experience navigating such regulatory pathways can be particularly valuable for emerging biotechnology companies developing novel genetic medicine platforms.
Earlier Experience at BioMarin and Amgen
Before joining BridgeBio Gene Therapy, Shaywitz spent five years at BioMarin Pharmaceutical, where he held progressively senior positions and ultimately served as Executive Medical Director.
At BioMarin, his responsibilities included leading clinical development programs in multiple rare diseases. His work encompassed both gene therapy and enzyme replacement therapy programs, providing experience with different therapeutic modalities and development strategies.
This background is relevant to SonoThera because the development of genetic medicines often requires a combination of specialized scientific understanding, clinical trial design and regulatory planning. Experience working across different modalities can help clinical leaders evaluate development risks and opportunities as new therapeutic technologies move into human testing.
Earlier in his career, Shaywitz served as a Medical Director at Amgen. In that role, he led first-in-human and Phase 1 development programs in cardiometabolic disease.
His experience with early-stage clinical development provides an additional dimension to his background. First-in-human and Phase 1 studies are critical stages for establishing initial safety, tolerability, pharmacokinetics and other clinical characteristics of new therapeutic candidates.
Taken together, his work at Amgen, BioMarin and BridgeBio has given Shaywitz experience across different therapeutic areas, development stages and technology platforms.
Strong Academic and Medical Training
Shaywitz’s scientific and medical background includes advanced training at Harvard Medical School. He earned both his M.D. and Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School, following an A.B. in Biochemistry from Harvard College.
He subsequently completed medical training at Massachusetts General Hospital and a fellowship in endocrinology, diabetes and metabolism at Beth Israel Deaconess Medical Center and Joslin Diabetes Center.
In addition to his industry experience, Shaywitz previously served as an Assistant Clinical Professor of Medicine at the UCLA School of Medicine. His academic and clinical training provides a foundation spanning biomedical research, medicine and patient care.
This combination of scientific training and industry experience is expected to support his role at SonoThera as the company evaluates how its technology can be translated into clinical development programs.
Supporting SonoThera’s Transition Toward the Clinic
The appointment of Shaywitz as Chief Medical Officer represents an important organizational development for SonoThera as it works toward bringing its pipeline into clinical development.
For biotechnology companies developing novel genetic medicine platforms, the transition from preclinical research to human clinical studies requires significant planning. Clinical trial design, patient selection, regulatory strategy, manufacturing considerations and translational research must be coordinated to establish a clear path toward clinical evaluation.
Shaywitz’s previous experience leading gene therapy programs through clinical and regulatory milestones positions him to contribute to these efforts.
His background may also support SonoThera’s efforts to identify appropriate development pathways for its candidates and establish strategies that can demonstrate the potential value of its technology in patients.
With Shaywitz joining as Chief Medical Officer, SonoThera is strengthening its leadership team as it advances its next-generation genetic medicine platform toward the clinic.
His nearly two decades of biopharmaceutical experience, including senior leadership positions at BridgeBio Gene Therapy and BioMarin and earlier clinical development work at Amgen, provides the company with expertise across rare disease, gene therapy, early-stage development and regulatory strategy.
At BridgeBio, Shaywitz helped advance AAV gene therapy programs for monogenic diseases and contributed to the development of BBP-812 for Canavan disease, including its FDA RMAT designation. His experience with both clinical development and organizational leadership is expected to be particularly relevant as SonoThera moves its own programs closer to clinical testing.
The company’s technology is designed to address fundamental delivery challenges that have limited the broader application of genetic medicines. With Shaywitz now leading medical and clinical development activities, SonoThera aims to translate its scientific platform into potential therapies that could address the root causes of disease.
As the company progresses toward clinical development, Shaywitz will work with SonoThera’s leadership and scientific teams to establish development strategies and help determine how the company’s technology can best be evaluated in patients.
The appointment underscores SonoThera’s focus on building the clinical expertise needed to advance innovative genetic medicine approaches from scientific discovery into potential new treatment options for patients with serious and rare diseases.
About SonoThera
SonoThera is developing an ultrasound-mediated, nonviral genetic medicine platform designed to deliver the next generation of safe, targeted, and redosable genetic medicines. By integrating proprietary RIPPLE™ ultrasound delivery with PORE™ payload engineering, the company is advancing a broad range of genetic medicine approaches, including DNA and RNA therapeutics, gene editing, and gene silencing.
SonoThera’s platform is designed to enable precise, durable gene expression across multiple tissues while addressing key limitations associated with viral delivery approaches. The company is advancing a pipeline of genetic medicines for serious diseases, including Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease. SonoThera is headquartered in South San Francisco, California.